91 related articles for article (PubMed ID: 24043736)
1. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
Evens AM; Advani R; Press OW; Lossos IS; Vose JM; Hernandez-Ilizaliturri FJ; Robinson BK; Otis S; Nadav Dagan L; Abdallah R; Kroll-Desrosiers A; Yarber JL; Sandoval J; Foyil K; Parker LM; Gordon LI; Blum KA; Flowers CR; Leonard JP; Habermann TM; Bartlett NL
J Clin Oncol; 2013 Nov; 31(32):4132-9. PubMed ID: 24043736
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Early Stages Hodgkin Lymphoma During Pregnancy.
Avilés A; Nambo MJ; Neri N
Mediterr J Hematol Infect Dis; 2018; 10(1):e2018006. PubMed ID: 29326803
[TBL] [Abstract][Full Text] [Related]
3. The Management of Lymphoma in the Setting of Pregnancy.
Pinnix CC; Andraos TY; Milgrom S; Fanale MA
Curr Hematol Malig Rep; 2017 Jun; 12(3):251-256. PubMed ID: 28470380
[TBL] [Abstract][Full Text] [Related]
4. Management of lymphoma in pregnancy.
Hodby K; Fields PA
Obstet Med; 2009 Jun; 2(2):46-51. PubMed ID: 27582811
[TBL] [Abstract][Full Text] [Related]
5. Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries.
Avivi I; Farbstein D; Brenner B; Horowitz NA
Blood Rev; 2014 Sep; 28(5):213-20. PubMed ID: 25108745
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
Landsburg DJ; Falkiewicz MK; Maly J; Blum KA; Howlett C; Feldman T; Mato AR; Hill BT; Li S; Medeiros LJ; Torka P; Hernandez-Ilizaliturri F; Reddy NM; Singavi A; Fenske TS; Chavez JC; Kaplan JB; Behdad A; Petrich AM; Bast MA; Vose JM; Olszewski AJ; Costa C; Lansigan F; Gerson JN; Barta SK; Calzada O; Cohen JB; Lue JK; Amengual JE; Rivera X; Persky DO; Peace DJ; Nathan S; Cassaday RD
J Clin Oncol; 2017 Jul; 35(20):2260-2267. PubMed ID: 28475457
[TBL] [Abstract][Full Text] [Related]
7. Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.
Gopal AK; Kahl BS; Flowers CR; Martin P; Ansell SM; Abella-Dominicis E; Koh B; Ye W; Barr PM; Salles GA; Friedberg JW
Blood; 2017 Jun; 129(22):3037-3039. PubMed ID: 28325864
[No Abstract] [Full Text] [Related]
8. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
Bartlett NL; Smith MR; Siddiqi T; Advani RH; O'Connor OA; Sharman JP; Feldman T; Savage KJ; Shustov AR; Diefenbach CS; Oki Y; Palanca-Wessels MC; Uttarwar M; Li M; Yang J; Jacobsen ED
Leuk Lymphoma; 2017 Jul; 58(7):1607-1616. PubMed ID: 27868471
[TBL] [Abstract][Full Text] [Related]
11. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.
Horwitz SM; Zelenetz AD; Gordon LI; Wierda WG; Abramson JS; Advani RH; Andreadis CB; Bartlett N; Byrd JC; Fayad LE; Fisher RI; Glenn MJ; Habermann TM; Lee Harris N; Hernandez-Ilizaliturri F; Hoppe RT; Kaminski MS; Kelsey CR; Kim YH; Krivacic S; LaCasce AS; Lunning M; Nademanee A; Press O; Rabinovitch R; Reddy N; Reid E; Roberts K; Saad AA; Sokol L; Swinnen LJ; Vose JM; Yahalom J; Zafar N; Dwyer M; Sundar H; Porcu P
J Natl Compr Canc Netw; 2016 Sep; 14(9):1067-79. PubMed ID: 27587620
[TBL] [Abstract][Full Text] [Related]
12. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wilson WH; Young RM; Schmitz R; Yang Y; Pittaluga S; Wright G; Lih CJ; Williams PM; Shaffer AL; Gerecitano J; de Vos S; Goy A; Kenkre VP; Barr PM; Blum KA; Shustov A; Advani R; Fowler NH; Vose JM; Elstrom RL; Habermann TM; Barrientos JC; McGreivy J; Fardis M; Chang BY; Clow F; Munneke B; Moussa D; Beaupre DM; Staudt LM
Nat Med; 2015 Aug; 21(8):922-6. PubMed ID: 26193343
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
Advani RH; Hong F; Fisher RI; Bartlett NL; Robinson KS; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Stewart DA; Gordon LI; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
J Clin Oncol; 2015 Jun; 33(17):1936-42. PubMed ID: 25897153
[TBL] [Abstract][Full Text] [Related]
14. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404).
Swinnen LJ; Li H; Quon A; Gascoyne R; Hong F; Ranheim EA; Habermann TM; Kahl BS; Horning SJ; Advani RH
Br J Haematol; 2015 Jul; 170(1):56-65. PubMed ID: 25823885
[TBL] [Abstract][Full Text] [Related]
15. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).
Wagner LI; Zhao F; Hong F; Williams ME; Gascoyne RD; Krauss JC; Advani RH; Go RS; Habermann TM; Leach JW; O'Connor B; Schuster SJ; Cella D; Horning SJ; Kahl BS
J Clin Oncol; 2015 Mar; 33(7):740-8. PubMed ID: 25605841
[TBL] [Abstract][Full Text] [Related]
16. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
[TBL] [Abstract][Full Text] [Related]
17. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
Hosein PJ; Maragulia JC; Salzberg MP; Press OW; Habermann TM; Vose JM; Bast M; Advani RH; Tibshirani R; Evens AM; Islam N; Leonard JP; Martin P; Zelenetz AD; Lossos IS
Br J Haematol; 2014 May; 165(3):358-63. PubMed ID: 24467658
[TBL] [Abstract][Full Text] [Related]
18. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.
Byrd JC; Pagel JM; Awan FT; Forero A; Flinn IW; Deauna-Limayo DP; Spurgeon SE; Andritsos LA; Gopal AK; Leonard JP; Eisenfeld AJ; Bannink JE; Stromatt SC; Furman RR
Blood; 2014 Feb; 123(9):1302-8. PubMed ID: 24381226
[TBL] [Abstract][Full Text] [Related]
20. An update on the management of hematologic malignancies in pregnancy.
Lavi N; Horowitz NA; Brenner B
Womens Health (Lond); 2014 May; 10(3):255-66. PubMed ID: 24956292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
